Chapter 7
Utilizing AI and Nanotechnology Solutions to Propel Progress in Cancer Diagnostics, Therapeutics, and Integrated Theranostics

Zahraa Saleh
https://orcid.org/0000-0002-0781-4096
Lebanese University, Lebanon & NanosTech, Lebanon

Wassim Jaber
https://orcid.org/0000-0003-0676-1719
NanosTech, USA

Ali Jaber
https://orcid.org/0000-0002-9180-8384
Lebanese University, Lebanon

Edmond Cheble
Lebanese University, Lebanon

Mikhael Bechelany
https://orcid.org/0000-0002-2913-2846
ENSCM, Centre National de la Recherche Scientifique (CNRS), University of Montpellier, France

Akram Hijazi
Independent Researcher, Lebanon

David Cornu
https://orcid.org/0000-0002-5205-3038
University of Montpellier, France

Ghassan Mahmoud Ibrahim
El Kut University College, Iraq

ABSTRACT

This chapter explores the dynamic convergence of nanotechnology and artificial intelligence (AI) in advancing cancer diagnosis and therapy. Nanotechnology employs nanoparticles for theragnostic applications, integrating diagnostic and therapeutic roles. Customized nanoparticles enable precise imaging and targeted treatment, minimizing harm to healthy tissue. Passive and active targeting optimize drug delivery, combat multidrug resistance, and introduce personalized treatment. AI-driven techniques analyze omics data and clinical information, enabling predictive models for immunotherapy and molecular target therapy. Next-gen sequencing reveals mutations and oncogenic pathways, with AI extracting insights from high-dimensional data. AI's integration into medical practice enhances diagnostics, catalyzing healthcare transformation. The synergy of nanotechnology and AI revolutionizes cancer management and reshapes medical practice.

DOI: 10.4018/979-8-3693-0368-9.ch007

INTRODUCTION

In spite of the cumulative progress achieved within the medical field, the domains of cancer diagnosis (Jin et al., 2020, Zhang et al., 2019) and treatment continue to exhibit limitations, underdevelopment, and inefficiencies (Jin et al., 2010). Presently employed conventional diagnostic methodologies struggle to identify the earliest indicators of cancer initiation, while conventional treatment protocols are hindered by pronounced toxicity, poor bioavailability, non-specific targeting, and the emergence of multi-drug resistance (Das & J, 2023). Consequently, the prognosis for cancer patients remains bleak, contributing to a persistent annual rise in cancer-related mortality rates (Zhang et al., 2019). Novel, more sophisticated tools need to be harnessed to produce diagnostic techniques of heightened sensitivity, alongside therapies that are targeted, precise, and safe to counteract drug resistance (Das & J, 2023). Nanotechnology offers avenues for innovative approaches, leveraging augmented physicochemical properties and capabilities to facilitate accurate and specific cancer diagnosis that transcends conventional practices (Jin et al., 2020, Zhang et al., 2019). Moreover, nanotechnology facilitates the engineering of delivery vehicles for targeted drug delivery that are markedly more efficient and safer, capable of addressing mechanisms of drug resistance (Das & J, 2023, Jin et al., 2020). Complementarily, artificial intelligence assumes a pivotal role in the analysis of extensive datasets, proving invaluable in the design and advancement of diagnostic and therapeutic paradigms rooted in nanotechnology. Additionally, artificial intelligence enables concurrent analysis of diagnostic data, enabling accurate deductions concerning evaluated cases and providing guidance for treatment monitoring (Das & J, 2023).

NANOTECHNOLOGY IN CANCER

Nanotechnology Advancements in Cancer Diagnostics

Cancer is initiated by genetic mutations that increase the transcription of certain biomolecules leading to uncontrolled growth of certain cell types. The tumor can be either benign and confined to its position, or malignant which casts cells that invade adjacent and consequently tissues and organs. Early diagnostic assays include the use of positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound imaging. Those assays can detect cancer only after a visible change in tissue had occurred, at this point multitudes of tumor cells have proliferated, and the tumor might have metastasized. Subsequently, there is a pressing need for developing more sensitive diagnostic techniques through the incorporation of nano-engineered particles and systems to revolutionize analytical modalities (Jin et al., 2020, Zhang et al., 2019).

Nanotechnology in Tumor Imaging

Various nanoparticles (NPs) have enhanced optical, magnetic, and structural properties as compared to their micro-sized counterparts, owing to their smaller size and much higher surface area-to-volume ratio (Jin et al., 2020). Examples of NPs used in tumor imaging assays include semiconductors, quantum dots, and iron oxide nanoparticles. NPs are used in conjunction with antitumor drugs or molecules to detect cancer with high specificity. The antitumor agent will bind to the tumor, and the NPs will aid in the elevated resolution of the tumor image for a more specific and earlier detection (Jin et al., 2020). An

Routing Physarum with Electrical Flow/Current
Soichiro Tsuda, Jeff Jones, Andrew Adamatzkyand Jonathan Mills (2011). *International Journal of Nanotechnology and Molecular Computation (pp. 56-70).*
www.irma-international.org/article/routing-physarum-electrical-flow-current/66397